Patents Issued in October 12, 2017
  • Publication number: 20170290808
    Abstract: The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor in combination with a small molecule chemokine receptor antagonist that blocks CCR1.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 12, 2017
    Inventors: Israel CHARO, Heiyoun JUNG, Thomas J. SCHALL, Penglie ZHANG
  • Publication number: 20170290809
    Abstract: The present invention relates to compounds which are found to exhibit an antiviral effect. The compounds are modulators of the activity of the viral haemagglutinin and/or neuraminidase enzymes.
    Type: Application
    Filed: September 7, 2015
    Publication date: October 12, 2017
    Applicant: Griffith University
    Inventors: Mark Von Itzstein, Ibrahim El-Deeb, Larissa Dirr, Patrice Guillon, Moritz Winger
  • Publication number: 20170290810
    Abstract: Pharmaceutical compositions for treating, mitigating or preventing fungal nail diseases, disorders or pathologies are described, the compositions comprising at least one functionalized allylamine compound, at least one functionalized triazole compound, and at least one functionalized imidazole compound. Methods for fabricating the compositions and using them are also described.
    Type: Application
    Filed: March 23, 2017
    Publication date: October 12, 2017
    Inventor: Dennis Elias Saadeh
  • Publication number: 20170290811
    Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.
    Type: Application
    Filed: June 16, 2017
    Publication date: October 12, 2017
    Inventors: Indrajit Ghosh, Jia-Ai Zhang
  • Publication number: 20170290812
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: March 13, 2017
    Publication date: October 12, 2017
    Inventors: RAPHAEL DARTEIL, ROBERT WALCZAK, CAROLE BELANGER, EMILIE NEGRO, PIERRE DAUBERSIES, PHILIPPE DELATAILLE
  • Publication number: 20170290813
    Abstract: The present invention relates to a synergistic combination of active ingredients for use in the treatment of fibrotic diseases.
    Type: Application
    Filed: March 13, 2017
    Publication date: October 12, 2017
    Inventors: ROBERT WALCZAK, CORINNE FOUCART, PHILIPPE DELATAILLE
  • Publication number: 20170290814
    Abstract: The present invention relates compounds useful and their use for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: March 13, 2017
    Publication date: October 12, 2017
    Inventors: MATHIEU DUBERNET, ROBERT WALCZAK, PHILIPPE DELATAILLE
  • Publication number: 20170290815
    Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a structure of: wherein A is a ring; Y1 and Y2 are each independently N or C with the proper valency; X1 and X2 are each independently —NH—, —O—, —CH2—O—, —NH—CH2—, or —N(CH3)—CH2—, provided that when at least one of X1 and X2 is —CH2—O—, —NH—CH2—, or —N(CH3)—CH2— then the —CH2— is directly connected to A; a and b are each independently 0 or 1; c and d are each independently 0 or 1; Z1 and Z2 are each independently a heterocyclic; and R1 and R2 are each independently optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, amino, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; provided that if Y1 and Y2 are each C, then a is 1 and b is 1; provided that if Y1 and Y2 are each N, then a is 0 and b is 0; provided that if Y1 is N and Y
    Type: Application
    Filed: October 1, 2015
    Publication date: October 12, 2017
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Cornell University
    Inventors: Lee A. McDermott, Prema C. Iyer, Richard A. Cerione, William P. Katt
  • Publication number: 20170290816
    Abstract: In one aspect, the invention provides compounds of Formula (I) or (II): (I) or (II) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3, R4, Z and G are defined as set forth in the disclosure. The invention also provides compounds of Formulae A and B and pharmaceutically acceptable salts and solvates thereof. Other aspects of the invention include the use of compounds of Formulae I, II, A, and B, and pharmaceutically acceptable salts and solvates thereof for the treatment of disorders responsive to modulation of one or more opioid receptors. In certain embodiments, the Compounds of the Invention are useful for treating pain.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 12, 2017
    Applicant: Purdue Pharma L.P.
    Inventors: Xiaoming Zhou, Laykea Tafesse, John J. Engel
  • Publication number: 20170290817
    Abstract: A compound of formula (I): which is 4-(3-fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl)butanoic acid, or a salt thereof.
    Type: Application
    Filed: September 22, 2015
    Publication date: October 12, 2017
    Inventors: Niall Andrew Anderson, Matthew Howard James Campbell-Crawford, Ashley Paul Hancock, John Martin Pritchard, Joanna Mary Redmond
  • Publication number: 20170290818
    Abstract: A compound according to formula (I) wherein R1 is hydrogen, cyclopropyl, or pyrazolyl, wherein said pyrazolyl is optionally substituted by one or two methyl groups; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 22, 2015
    Publication date: October 12, 2017
    Inventors: Niall Andrew ANDERSON, Matthew Howard James CAMPBELL-CRAWFORD, Ashley Paul HANCOCK, Seble LEMMA, Simon John Fawcett MACDONALD, John Martin PRITCHARD, Panayiotis Alexandrou PROCOPIOU, Stephen SWANSON
  • Publication number: 20170290819
    Abstract: The present disclosure relates to pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) and its derivatives and pharmaceutically acceptable salts thereof, use of these compounds as a medicament, and for the manufacture of a medicament for treating or delaying the onset or development of pulmonary hypertension.
    Type: Application
    Filed: April 7, 2017
    Publication date: October 12, 2017
    Inventors: Yaping Tu, Yan Xie, Peter Abel
  • Publication number: 20170290820
    Abstract: Compounds, pharmaceutical compositions, and methods for treating anemia ?-thalassemia anemia or sickle cell anemia.
    Type: Application
    Filed: April 25, 2017
    Publication date: October 12, 2017
    Applicant: Academia Sinica
    Inventors: Che-Kun James Shen, Yu-Chi Chou, Tsann-Long Su
  • Publication number: 20170290821
    Abstract: The present invention provides an anti-influenza virus agent that targets biomolecules of host cells including human cells and a method of screening a candidate molecule for the anti-influenza virus agent. That is, the present invention is an anti-influenza virus agent that has an effect of suppressing expression or a function of a gene that encodes a protein having an effect of suppressing incorporation of an influenza virus vRNA or an NP protein into influenza virus-like particles in host cells and the gene is at least one selected from the group including JAK1 gene and the like.
    Type: Application
    Filed: September 18, 2015
    Publication date: October 12, 2017
    Applicant: Japan Science and Technology Agency
    Inventors: Yoshihiro KAWAOKA, Tokiko WATANABE, Eiryo KAWAKAMI, Shinji WATANABE
  • Publication number: 20170290822
    Abstract: This application provides for a method of treating a human patient afflicted with anti-TNF? refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 12, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
  • Publication number: 20170290823
    Abstract: Compositions and methods for treatment of Parkinson's disease to reduce the negative side effects of the disease by administering a therapeutically effective diarylmethylpiperazine compound which exhibits delta opioid receptor agonist activity, and optionally, mu receptor antagonist activity.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 12, 2017
    Inventors: KWEN-JEN CHANG, WILLIAM PENDERGAST, JONATHON D.S. HOLT
  • Publication number: 20170290824
    Abstract: A compound which is useful as an active ingredient for a pharmaceutical composition for treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. The present inventors have found that a 2-aminothiazole derivative has an excellent muscarinic M3 receptor-positive allosteric modulator activity and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-aminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.
    Type: Application
    Filed: August 25, 2015
    Publication date: October 12, 2017
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Taisuke TAKAHASHI, Hiroaki TANAKA, Michinori AKAIWA, Kenji NEGORO, Hisashi MIHARA, Hideyoshi FUJI, Hajime TAKAMATSU
  • Publication number: 20170290825
    Abstract: Described herein are methods for using compounds that activate pyruvate kinase.
    Type: Application
    Filed: May 1, 2017
    Publication date: October 12, 2017
    Inventor: Shin-San Michael Su
  • Publication number: 20170290826
    Abstract: Invented is a method of treating cancer or a pre-cancerous syndrome in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a non-peptide thrombopoietin (TPO) receptor agonist to such mammal, suitably a human.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 12, 2017
    Applicant: NOVARTIS AG
    Inventor: Connie L. ERICKSON-MILLER
  • Publication number: 20170290827
    Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
    Type: Application
    Filed: April 14, 2017
    Publication date: October 12, 2017
    Inventors: Kyla Bjornson, Eda Canales, Jeromy J. Cottell, Kapil K. Karki, Ashley A. Katana, Darryl Kato, Tetsuya Kobayashi, John O. Link, Ruben Martinez, Barton W. Phillips, Hyung-Jung Pyun, Michael Sangi, Adam J. Schrier, Dustin Siegel, James G. Taylor, Chinh V. Tran, Teresa Alejandra Trejo Martin, Randall W. Vivian, Zheng-Yu Yang, Jeff Zablocki, Sheila M. Zipfel
  • Publication number: 20170290828
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: November 29, 2016
    Publication date: October 12, 2017
    Inventors: Atwood Kim CHEUNG, Donovan Noel CHIN, Natalie DALES, Aleem FAZAL, Timothy HURLEY, John KERRIGAN, Gary O'BRIEN, Lei SHU, Robert SUN, Moo Je SUNG
  • Publication number: 20170290829
    Abstract: The invention relates to pimobendan for use in a method of reducing the heart size and/or delaying the onset of clinical symptoms in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), and/or delaying the onset of heart failure, preferably congestive heart failure, in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), wherein the patient is preferably a mammal, more preferably a human, a dog, a cat or a horse, and most preferably a dog.
    Type: Application
    Filed: April 3, 2017
    Publication date: October 12, 2017
    Inventors: Christoph SCHUMMER, Olaf JOENS
  • Publication number: 20170290830
    Abstract: Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 12, 2017
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: Bert W. O'Malley, David Michael Lonard, Jin Wang, Jianming Xu, Jianwei Chen
  • Publication number: 20170290831
    Abstract: A modified microbubble is provided. The modified microbubble includes an albumin microbubble and a plurality of chitosan oligosaccharide lactates. The albumin microbubble includes an albumin shell and a gas core inside the albumin shell. The plurality of chitosan oligosaccharide lactates is connected to an outer surface of the albumin shell.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 12, 2017
    Inventors: Ai-Ho LIAO, Chih-Hung WANG
  • Publication number: 20170290832
    Abstract: The present invention is directed to imidazolin-5-one derivatives, pharmaceutical compositions containing them, and their use as FASN inhibitors, in for example, the treatment of cancer, obesity related disorders, and liver related disorders.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 12, 2017
    Inventors: Peter J. Connolly, Tianbao Lu
  • Publication number: 20170290833
    Abstract: This application relates to various salts and solid state forms of Compound (I). This application also relates to pharmaceutical compositions and therapeutic uses of these materials and compositions.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 12, 2017
    Applicant: IGNYTA, INC.
    Inventors: Stephen J. BIERLMAIER, Ralph C. HALTIWANGER, Martin J. JACOBS
  • Publication number: 20170290834
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: November 28, 2016
    Publication date: October 12, 2017
    Inventors: Andrea WOLKERSTORFER, Oliver SZOLAR, Norbert HANDLER, Helmut BUSCHMANN, Stephen CUSACK, Mark SMITH, Sung-Sau So, Ronald Charles Hawley, Achyutharao Sidduri
  • Publication number: 20170290835
    Abstract: A pharmaceutical composition is provided which includes a pharmaceutically acceptable excipient and a pharmaceutically and physically acceptable amount of a compound selected from the group consisting of Chemical Formulas I-IV as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods of increasing a level of a defined neurotrophic peptide in an organism or tissue comprising the administration of a pharmaceutically and physically acceptable amount of one or more of the compositions described above, and a method for treating a neurodegenerative disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 1.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 12, 2017
    Inventor: John M. Beale
  • Publication number: 20170290836
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 12, 2017
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Publication number: 20170290837
    Abstract: The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: November 22, 2016
    Publication date: October 12, 2017
    Inventors: Kevin Wayne Kuntz, John Emmerson Campbell, Masashi Seki
  • Publication number: 20170290838
    Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8? are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.
    Type: Application
    Filed: April 28, 2017
    Publication date: October 12, 2017
    Inventors: Scott K. Thompson, Roger A. Smith, Sanjeeva Reddy, Tyler M. John, Vijay Kumar Nyavanandi, Hosahalli Subramanya, Vijay Potluri, Sunil Kumar Panigrahi, Prabhakara Rao Nadipalli, Saumitra Sengupta
  • Publication number: 20170290839
    Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 12, 2017
    Inventors: Liang Lu, Bo Shen, Alexander Sokolsky, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Yingda Ye
  • Publication number: 20170290840
    Abstract: The present invention provides a novel corneal thickness modulating agent. The present invention pertains to a corneal thickness modulating agent containing 1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof or a solvate thereof.
    Type: Application
    Filed: September 24, 2015
    Publication date: October 12, 2017
    Applicant: KOWA COMPANY, LTD.
    Inventors: Hiroyuki Takahashi, Kiyoshi Toya, Akifumi Tsuchiura
  • Publication number: 20170290841
    Abstract: An aqueous composition having an excellent antiseptic effect is provided. An aqueous composition comprising a compound represented by Formula (1), wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and a quaternary ammonium surfactant.
    Type: Application
    Filed: September 25, 2015
    Publication date: October 12, 2017
    Applicant: KOWA COMPANY, LTD.
    Inventor: Shin SUGIMOTO
  • Publication number: 20170290842
    Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.
    Type: Application
    Filed: June 19, 2017
    Publication date: October 12, 2017
    Applicant: Tel HaShomer Medical Research Infrastructure and Services, Ltd.
    Inventors: Anat ACHIRON, Roi MASHIACH, Michael GUREVICH
  • Publication number: 20170290843
    Abstract: A method of increasing abundance of hematopoietic stem cells and progenitor cells and an adjuvant method of radiotherapy based treatment for radioprotection of the subject against ?-radiation toxicity and/or IR-induced death of cancer cells involving pharmaceutically effective dosages of chlorophyllin or a pharmaceutically acceptable salt thereof. The advancement is directed to selectively protect normal hematopoietic stem cells and/or sensitizes radio-resistant cancer cells to gamma radiation thereby lowering the risk of normal tissue radiation toxicity. The effective dose of the CHL formulation synergistically improves the outcome of radiotherapy for cancer when administered to the subject prior the radiotherapy for treating cancer. Also disclosed is kit having chlorophyllin containing therapeutic preparation for treating indications selected from reduction in hematopoietic stem cells and progenitor cells (HSPCs) and/or protection against whole body irradiation induced mortality.
    Type: Application
    Filed: April 8, 2016
    Publication date: October 12, 2017
    Inventors: Deepak Sharma, Santosh Kumar Sandur, Rahul Checker, Raghavendra Shridhar Patwardhan, Vikram Prakash Gota, Jayakumar Sundarraj, Preetha Sasi, Subrata Chattopadhyay
  • Publication number: 20170290844
    Abstract: The present invention relates to methods of treating or preventing respiratory infections, in particular respiratory infections in patients with an underlying respiratory disorder such as chronic obstructive pulmonary disease (COPD). The present invention also relates to methods of treating or preventing COPD or COPD exacerbations. The invention particularly describes the role of Notch 3 and/or Notch 4 signalling in such methods and the use of Notch 3 and/or Notch 4 as therapeutic and screening targets.
    Type: Application
    Filed: September 22, 2015
    Publication date: October 12, 2017
    Inventors: Soren BEINKE, Nikolai Nikolaevich BELYAEV, Edith HESSEL
  • Publication number: 20170290845
    Abstract: Provided are methods for slowing, halting, and reversing gray matter atrophy and progression of disability in certain neurodegenerative diseases, including multiple sclerosis, using estrogen, alone or in combination with another agent.
    Type: Application
    Filed: September 1, 2015
    Publication date: October 12, 2017
    Applicant: The Regents of the University of California
    Inventor: Rhonda R. Voskuhl
  • Publication number: 20170290846
    Abstract: The present invention relates to an injectable polymer matrix drug delivery system comprising a biodegradable polymer, a solvent or a combination of solvents, and an active pharmaceutical ingredient.
    Type: Application
    Filed: September 30, 2015
    Publication date: October 12, 2017
    Inventors: Tao L. Lowe, James Johnson, Linfeng Wu
  • Publication number: 20170290847
    Abstract: Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low DHEA or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (DHEA) and a selective estrogen receptor modulator (SERM) (particularly acolbifene), an antiestrogen or a prodrug of the two.
    Type: Application
    Filed: June 19, 2017
    Publication date: October 12, 2017
    Inventors: Fernand Labrie, Sylvain Gauthier
  • Publication number: 20170290848
    Abstract: This disclosure relates to compositions, kits and methods for non-surgical reduction of localized subcutaneous fat such as that associated with a cosmetic fat accumulation. The methods employ compositions having specific concentrations of a salt of deoxycholic acid which provides a superior fat cell necrosis with modest adverse effects. Examples of localized subcutaneous fat are found in the submental area, in particular under the chin.
    Type: Application
    Filed: April 27, 2017
    Publication date: October 12, 2017
    Applicant: Kythera Biopharmaceuticals, Inc.
    Inventor: Patricia Walker
  • Publication number: 20170290849
    Abstract: A mechanism whereby aberrant Shh signaling converges on the Akt1-mTOR pathway, conferring selective growth advantage and enhanced survival of tumor cells has been identified. Utilizing a mouse model of BCNS, a pivotal role has been discovered for Akt1 signaling in BCC tumorigenesis. Based on the results described here certain embodiments are directed to methods and pharmaceutical formulations for treating BCC/BCNS, other cancers that are Shh+ and Akt+, cancers that are Shh+ and mTOR plus and cancers that are Shh+ by administering therapeutically effective amounts of various combinations of Akt inhibitors, Shh pathway inhibitors such as SMO inhibitors, and mTOR inhibitors.
    Type: Application
    Filed: September 8, 2015
    Publication date: October 12, 2017
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Arianna L. Kim, David Bickers, Mohammad Athar
  • Publication number: 20170290850
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Application
    Filed: August 5, 2016
    Publication date: October 12, 2017
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczpankiewicz, Jonathan N. Kremsky
  • Publication number: 20170290851
    Abstract: The present invention provides a method of treating or preventing type 2 diabetes and hyperlipidemia in a subject in need thereof, comprising administrating to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a pharmaceutical composition for treatment or prevention of type 2 diabetes and hyperlipidemia, comprising a compound of formula I and a pharmaceutically acceptable carrier. Through down-regulation of PEPCK, G6Pase, 11?-HSD1, DGAT2, and GPAT, up-regulation of PPAR? and adiponectin, and promotion of membrane GLUT4 expression and phosphorylation of AMPK and Akt, the compound of formula I of the present invention exerts antidiabetic and antihyperlipidemic effects, including reduced weight of visceral fat, decreased blood levels of triglycerides, free fatty acids, glucose, insulin, and leptin as well as decreased hepatic levels of total lipid and triacylglycerol. The compound of formula I also inhibits adipocyte hypertrophy and hepatic ballooning.
    Type: Application
    Filed: October 10, 2016
    Publication date: October 12, 2017
    Inventor: Chun-Ching SHIH
  • Publication number: 20170290852
    Abstract: The present technology relates generally to micelle formulations of amphotericin B that optionally include 5-fluorocytosine and methods of preparing such formulations. Methods of treating fungal infections with the present compositions are also provided.
    Type: Application
    Filed: April 7, 2017
    Publication date: October 12, 2017
    Inventor: Glen S. KWON
  • Publication number: 20170290853
    Abstract: The present application relates to methods to facilitate the solubilization of beta-1,3-glucan in solution, for instance an aqueous or organic solvent and uses thereof to enhance immune function in an individual. Others aspects of the present invention relate to administering compositions or mixtures comprising solubilized beta-1,3-glucan to enhance immune function in humans or animals.
    Type: Application
    Filed: April 12, 2017
    Publication date: October 12, 2017
    Inventors: Geoffrey Paul HORST, Robert Bernard LEVINE
  • Publication number: 20170290854
    Abstract: In various embodiments, the present application teaches numerous compositions that include water clusters and methods of use thereof. In some embodiments, the present application teaches compositions and methods for treating, preventing and promoting the prophylaxis of bacterial infections in plants and animals. The present application further teaches compositions and methods for treating the surfaces of non-living substrates upon which bacteria are known or thought to reside. The present invention also teaches methods for adding compositions that include water clusters to foods and feed.
    Type: Application
    Filed: September 11, 2015
    Publication date: October 12, 2017
    Applicant: K10 Technologies, Inc.
    Inventor: John Matlick
  • Publication number: 20170290855
    Abstract: A silicate-doped hydroxyapatite material has an ordered and directional growth structure. The silicon content in the silicate-doped hydroxyapatite material ranges from 0.1 wt % to 1.6 wt %, and silicon is doped in hydroxyapatite lattices in a form of silicate. A template-induced method for manufacturing the synthetic silicate-doped hydroxyapatite material above.
    Type: Application
    Filed: January 13, 2017
    Publication date: October 12, 2017
    Inventors: Qin YANG, Yingying Du, Jianglin Wang
  • Publication number: 20170290856
    Abstract: Activated carbon (for example medicinal carbon), which has long been used for adsorbing and removing harmful substances from the digestive system, has the drawback of causing constipation, and the production of a spherical adsorbent carbon that is believed to overcome this drawback from a petroleum-based hydrocarbon requires a complicated production process. These issues can be addressed by an oral adsorbent, a therapeutic or prophylactic agent for kidney disease, and a therapeutic or prophylactic agent for liver disease, containing a fibrous carbonaceous substance obtained by carbonizing cotton fiber. The issues can also be addressed by an oral adsorbent, a therapeutic or prophylactic agent for kidney disease, and a therapeutic or prophylactic agent for liver disease, containing a fibrous carbonaceous substance having a twisted hollow ribbon-like structure.
    Type: Application
    Filed: September 24, 2014
    Publication date: October 12, 2017
    Applicant: Power Japan Plus Inc.
    Inventors: Dou KANI, Hiroaki NISHINA, Kaname TAKEYA, Masami KIDO, Nobuo KUBO
  • Publication number: 20170290857
    Abstract: The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.
    Type: Application
    Filed: June 22, 2017
    Publication date: October 12, 2017
    Inventor: Michael Har-Noy